Companies / Canada
Health Canada Investigates Janssen-Ortho's Contraceptive Patch
April 2006 | Company Finance AlertThe Canadian regulatory authority - Health Canada - is investigating Janssen-Ortho's Evra (ethinylestradiol + norelgestromin) contraceptive patch after two studies showed use of the US version of the product was associated with increased blood clots. The authority says the medication should be discontinued at the first instance of abnormal blood clotting. The version of Evra marketed in Canada is manufactured differently and contains less oestrogen than the US
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
